SLC12A5 and myeloid sarcoma: In contrast, SLC12A5 expression levels were significantly decreased in epilepsy (control mean ± SD = − 0.086 ± 0.486, KA mean ± SD = − 1.428 ± 0.192, p = 0.028, Student's t-test) but not in demyelinating diseases [control median (IQR) = − 1.530 (1.246), MS median (IQR) = − 1.955 (0.451), p = 0.237, Wilcoxon test].